News - Adempas, riociguat

Filter

Current filters:

Adempasriociguat

Popular Filters

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

Japanese approval for Bayer’s riociguat for CTEPH

Japanese approval for Bayer’s riociguat for CTEPH

20-01-2014

German pharma major Bayer has received approval from the Ministry of Health, Labor and Welfare for riociguat,…

AdempasAsia-PacificBayerPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

Long-awaited vaccine brings hope for millions

Long-awaited vaccine brings hope for millions

11-10-2013

Here's our take on the week's top stories.

AdempasEuropeGlaxoSmithKlineIclusigNorth America

Bayer gains two orphan drug designations for riociguat

Bayer gains two orphan drug designations for riociguat

26-09-2013

Bayer’s investigational drug riociguat has been granted two orphan drug designations by the US Food…

BayerNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

Bayer's PAH/CTEPH drug gets unanimous backing from FDA advisory panel

07-08-2013

In what was largely expected following this week's briefing papers from US Food and Drug Administration…

AdempasBayerNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

FDA staffers back riociguat approval, but with modified dose

05-08-2013

On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

Bayer presents strong Ph III riociguat data, which met primary endpoint in PAH

23-10-2012

Germany's Bayer (BAYN: DE) HealthCare unit yesterday announced positive data for riociguat from the pivotal…

BayerPharmaceuticalResearchRespiratory and Pulmonaryriociguat

Company Spotlight

Fibrotech

Fibrotech

Back to top